+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 12Years - 65Years
All Genders
ID07904195

Randomized, Double-blind Trial of Mannan-conjugated Allergoids for Treating Mite-induced Allergic Rhinitis and Rhinoconjunctivitis

Led by Inmunotek S.L. · Updated on 2026-10-29

250

Participants Needed

16

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating whether EP-088MM09, which contains modified house dust mite allergens called mannan-conjugated allergoids, can treat house dust mite allergy. This Phase 3 clinical trial involves 250 participants aged 12 to 65 years with persistent moderate to severe nasal allergy symptoms, with or without eye symptoms, and possibly mild or moderate controlled allergic asthma. The study aims to compare the treatments effect on allergy symptoms and the need for relief medicines against a placebo while assessing safety. Participants will be randomly assigned to receive either EP-088MM09 or a placebo, both given as subcutaneous injections. The treatment phase includes 12 monthly visits where participants receive injections under the skin the first visit involves two injections, and subsequent visits involve one injection each. Some participants sensitive to pollen may have an additional baseline visit to ensure symptom assessments avoid pollen season influence. After completing treatment, a final follow-up visit occurs about one month later. Throughout the study, participants will attend screening visits to confirm eligibility, complete daily symptom and medication diaries during specified periods, and provide blood samples and questionnaires on symptoms and quality of life. Clinic visits include monitoring of health and medication use, with participants staying at the clinic for at least 30 minutes after each injection. The main outcome measured is a combined score of symptoms and medication use over four weeks following treatment. Participation lasts approximately 14 to 21 months.

CONDITIONS

Brief Title

Specific Immunotherapy With Mannan-Conjugated Allergoids for HDM-Allergic Rhinitis/Rhinoconjunctivitis_MM09-SIT-063.

Research Team

R

Raquel Caballero

M

Marta Romero

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here